Intas Pharmaceuticals Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Intas Pharmaceuticals Ltd. - overview
Established
1976
Location
Ahmedabad, Gujarat, India
Primary Industry
Pharmaceuticals
About
Intas Pharmaceuticals Ltd. is a pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of high-quality pharmaceutical formulations and innovative healthcare solutions. Founded in 1976, Intas Pharmaceuticals Ltd. operates out of Ahmedabad, India, focusing on producing generics, oncology products, and parenteral solutions.
The company has undergone strategic pivots to enhance its product offerings and market reach. It is not a subsidiary of any parent company and has not been formed through a merger or carve-out. Intas has raised a total of USD 250. 00 mn, with its latest funding round being a LP Direct trade sale involving investors such as the Abu Dhabi Investment Authority.
Intas Pharmaceuticals Ltd. specializes in the development and production of a diverse range of pharmaceutical formulations, including generics, oncology products, parenteral solutions, and added-value products. Its innovative treatments address critical healthcare needs, including THYMOTAS, an immuno-booster for COVID-19, and Romiplostim for chronic immune thrombocytopenia (ITP). Intas markets its products primarily to healthcare professionals across over 85 countries, with significant presence in the European Union and the United States.
In the most recent year of 2023, Intas Pharmaceuticals reported a revenue of USD 2,477. 38 mn and an EBITDA of USD 469. 43 mn. Approximately 70% of its income is generated from international markets through direct sales and partnerships with pharmaceutical distributors, enhancing its extensive product portfolio.
Intas Pharmaceuticals plans to launch new products designed to meet emerging healthcare demands and expand into new geographic markets, with specific focuses on the Asia-Pacific region and select European countries by the end of 2024. The recent funding of USD 250. 00 mn will be utilized to bolster research and development initiatives and support the introduction of new therapies. Additionally, the company is adapting to market changes following ChrysCapital's exit from its stake, which indicates a strategic shift in investment and operational strategies.
Current Investors
ChrysCapital
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.intaspharma.com/
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Intas Pharmaceuticals Ltd. - timeline of key events
Intas Pharmaceuticals Ltd. - financials
| Fiscal Year Ended | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 33,976,677,280.6 | 40,957,989,083 | 45,425,892,035 | 65,691,516,000.3 | 83,841,943,000 | 108,861,740,000 | 131,100,220,000 | 148,544,710,000 | 164,700,960,000 | - | - | - |
| % Revenue Growth (YoY) | - | 20.5% | 10.9% | 44.6% | 27.6% | 29.8% | 20.4% | 13.3% | 10.9% | - | - | - |
| EBITDA (USD) | 7,586,367,042.8 | 8,454,848,733 | 8,838,256,258 | 14,685,217,547.6 | 17,696,551,000 | 24,532,670,000 | 24,989,950,000 | 34,122,470,000 | 37,561,600,000 | - | - | - |
| Operating Income (USD) | 6,831,797,333.7 | 7,481,774,172 | 7,541,336,071 | 11,980,803,816.6 | 14,724,318,000 | 20,206,050,000 | 19,897,480,000 | 26,717,470,000 | 30,459,050,000 | - | - | - |
| Operating Margin | 20.1% | 18.3% | 16.6% | 18.2% | 17.6% | 18.6% | 15.2% | 18.0% | 18.5% | - | - | - |
| % EBITDA Margin | 22.3% | 20.6% | 19.5% | 22.4% | 21.1% | 22.5% | 19.1% | 23.0% | 22.8% | - | - | - |
| NET Income (USD) | 5,469,954,730.4 | 6,072,523,104 | 6,290,381,394 | 8,824,948,416.4 | 10,313,119,000 | 13,666,520,000 | 14,192,380,000 | 16,405,660,000 | 22,898,090,000 | - | - | - |
| % Net Margin | 16.1% | 14.8% | 13.8% | 13.4% | 12.3% | 12.6% | 10.8% | 11.0% | 13.9% | - | - | - |
Intas Pharmaceuticals Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Corporate Carve Out, Trade Sale | Completed | UDENYCA® | - | ||||||||
| LP Direct, Trade Sale | Completed | Intas Pharmaceuticals Ltd. | - | ||||||||
| Secondary Buyout | Completed | Intas Pharmaceuticals Ltd. | - | ||||||||
| Secondary Buyout | Completed | Intas Pharmaceuticals Ltd. | - | ||||||||
| Growth | Completed | Intas Pharmaceuticals Ltd. | - |
Displaying 1 - 5 of 11
Intas Pharmaceuticals Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.